RU2012144612A - Способ и композиции для интраназальной доставки - Google Patents
Способ и композиции для интраназальной доставки Download PDFInfo
- Publication number
- RU2012144612A RU2012144612A RU2012144612/15A RU2012144612A RU2012144612A RU 2012144612 A RU2012144612 A RU 2012144612A RU 2012144612/15 A RU2012144612/15 A RU 2012144612/15A RU 2012144612 A RU2012144612 A RU 2012144612A RU 2012144612 A RU2012144612 A RU 2012144612A
- Authority
- RU
- Russia
- Prior art keywords
- antigens
- dry powder
- vaccine
- specified
- paragraph
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 54
- 238000000034 method Methods 0.000 title claims 66
- 239000000427 antigen Substances 0.000 claims abstract 69
- 102000036639 antigens Human genes 0.000 claims abstract 69
- 108091007433 antigens Proteins 0.000 claims abstract 69
- 239000000843 powder Substances 0.000 claims abstract 50
- 229960005486 vaccine Drugs 0.000 claims abstract 45
- 241000712461 unidentified influenza virus Species 0.000 claims abstract 24
- 241000700605 Viruses Species 0.000 claims abstract 16
- 150000001720 carbohydrates Chemical class 0.000 claims abstract 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract 7
- 230000002238 attenuated effect Effects 0.000 claims abstract 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract 7
- 206010069767 H1N1 influenza Diseases 0.000 claims abstract 6
- 201000010740 swine influenza Diseases 0.000 claims abstract 6
- 230000001580 bacterial effect Effects 0.000 claims abstract 4
- 230000003612 virological effect Effects 0.000 claims abstract 4
- 239000000277 virosome Substances 0.000 claims abstract 4
- 241001500350 Influenzavirus B Species 0.000 claims abstract 2
- 239000007788 liquid Substances 0.000 claims 9
- 230000008014 freezing Effects 0.000 claims 8
- 238000007710 freezing Methods 0.000 claims 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 241000894006 Bacteria Species 0.000 claims 6
- 102000018697 Membrane Proteins Human genes 0.000 claims 6
- 108010052285 Membrane Proteins Proteins 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 6
- 239000002245 particle Substances 0.000 claims 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 4
- 239000000969 carrier Substances 0.000 claims 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 4
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 206010064097 avian influenza Diseases 0.000 claims 3
- 229960003983 diphtheria toxoid Drugs 0.000 claims 3
- 239000008101 lactose Substances 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 239000008363 phosphate buffer Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 229960000814 tetanus toxoid Drugs 0.000 claims 3
- 241000713196 Influenza B virus Species 0.000 claims 2
- 241001591005 Siga Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M3/00—Automatic or semi-automatic exchanges
- H04M3/42—Systems providing special services or facilities to subscribers
- H04M3/50—Centralised arrangements for answering calls; Centralised arrangements for recording messages for absent or busy subscribers ; Centralised arrangements for recording messages
- H04M3/51—Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing
- H04M3/5116—Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing for emergency applications
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/90—Services for handling of emergency or hazardous situations, e.g. earthquake and tsunami warning systems [ETWS]
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W76/00—Connection management
- H04W76/50—Connection management for emergency connections
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W76/00—Connection management
- H04W76/10—Connection setup
- H04W76/15—Setup of multiple wireless link connections
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W8/00—Network data management
- H04W8/18—Processing of user or subscriber data, e.g. subscribed services, user preferences or user profiles; Transfer of user or subscriber data
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Business, Economics & Management (AREA)
- Signal Processing (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Computer Networks & Wireless Communication (AREA)
- Emergency Management (AREA)
- Environmental & Geological Engineering (AREA)
- Marketing (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32454210P | 2010-04-15 | 2010-04-15 | |
| US61/324,542 | 2010-04-15 | ||
| PCT/JP2011/002225 WO2011129120A1 (en) | 2010-04-15 | 2011-04-15 | Methods and compositions for intranasal delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012144612A true RU2012144612A (ru) | 2014-05-20 |
Family
ID=44798502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012144612/15A RU2012144612A (ru) | 2010-04-15 | 2011-04-15 | Способ и композиции для интраназальной доставки |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9687536B2 (https=) |
| EP (2) | EP2689785B1 (https=) |
| JP (5) | JP5771626B2 (https=) |
| KR (3) | KR102136036B1 (https=) |
| CN (3) | CN102933230B (https=) |
| BR (1) | BR112012026116A2 (https=) |
| CA (2) | CA2796593C (https=) |
| CU (1) | CU20120148A7 (https=) |
| ES (1) | ES2874817T3 (https=) |
| RU (1) | RU2012144612A (https=) |
| SG (1) | SG184304A1 (https=) |
| WO (1) | WO2011129120A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102933230B (zh) * | 2010-04-15 | 2016-03-02 | 株式会社新日本科学 | 用于鼻内递送的方法和组合物 |
| US9795773B2 (en) | 2011-12-16 | 2017-10-24 | Indosys Limited | Medicament unit dose cartridge and delivery device |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| WO2014186754A2 (en) | 2013-05-16 | 2014-11-20 | Board Of Regents The University Of Texas System | Dry solid aluminum adjuvant-containing vaccines and related methods thereof |
| CN104208029B (zh) * | 2013-05-30 | 2017-06-06 | 上海医药工业研究院 | 一种鼻用疫苗组合物粉体制剂及其制备方法 |
| RU2720808C2 (ru) * | 2013-09-03 | 2020-05-13 | Джорджия Тек Рисёч Корпорейшн | Термостабильные препараты вакцин и микроиглы |
| EP4008307A1 (en) * | 2013-09-24 | 2022-06-08 | Satsuma Pharmaceuticals, Inc. | Intranasal dhe formulation for the treatment of headache |
| IL310015B2 (en) | 2013-12-31 | 2026-02-01 | Access To Advanced Health Inst | Single vial formulation |
| EP3127550A1 (en) * | 2015-08-07 | 2017-02-08 | HSC Development GmbH | Stabilizing composition for dry formulation of virus |
| JP2018533547A (ja) * | 2015-09-16 | 2018-11-15 | 株式会社新日本科学 | ワクチン組成物 |
| GB201610628D0 (en) * | 2016-06-17 | 2016-08-03 | Mihranyan Albert | New compositions |
| WO2018053524A1 (en) * | 2016-09-19 | 2018-03-22 | Vaxess Technologies, Inc. | Vaccine formulations with increased stability |
| US11022115B2 (en) | 2017-06-02 | 2021-06-01 | Purdue Research Foundation | Controlled variable delivery external gear machine |
| JPWO2019021957A1 (ja) * | 2017-07-25 | 2020-07-09 | 第一三共株式会社 | 点鼻用乾燥粉末医薬組成物 |
| GB201713899D0 (en) | 2017-08-30 | 2017-10-11 | Indosys Ltd | Multi-dose medicament delivery device |
| US11918646B2 (en) | 2017-12-11 | 2024-03-05 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
| EP3847246A1 (en) * | 2018-09-06 | 2021-07-14 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| WO2020123607A1 (en) | 2018-12-11 | 2020-06-18 | Satsuma Pharmaceuticals, Inc. | Compositions, devices, and methods for treating or preventing headaches |
| JP7660514B2 (ja) * | 2019-02-15 | 2025-04-11 | セラム インスティチュート オブ インディア プライベイト リミテッド | 弱毒生インフルエンザワクチン組成物及びその調製プロセス |
| EP3698773A1 (en) | 2019-02-21 | 2020-08-26 | Università degli Studi di Parma | Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination |
| US11621604B2 (en) | 2020-02-16 | 2023-04-04 | Purdue Research Foundation | Integrated electro-hydraulic machine |
| CA3175456A1 (en) * | 2020-03-24 | 2021-09-30 | Byung Chul Ahn | Method of producing serum composition for preventing or treating mucosa-related infectious disease in young mammals, serum composition produced thereby, and use thereof |
| CN113583970B (zh) * | 2021-07-29 | 2023-05-12 | 吉林大学 | 一种用于预防或抗冠状病毒传播、致病的药物及其制备方法 |
| CN119866231A (zh) | 2022-09-01 | 2025-04-22 | 锡拉坎岛有限公司 | 干粉药物递送装置 |
| EP4630460A1 (en) * | 2022-12-07 | 2025-10-15 | Daocheng Zhu | Formulation and use of a fusion protein |
| WO2024228212A1 (en) * | 2023-05-01 | 2024-11-07 | Biovet Private Limited | Bio-lumpivaxin formulations and method of preparation thereof |
| WO2024246607A1 (en) * | 2023-05-31 | 2024-12-05 | Shin Nippon Biomedical Laboratories, Ltd. | Compositions for enhanced mucosal penetration |
| GB202403611D0 (en) | 2024-03-13 | 2024-04-24 | Therakind Ltd | Improved multi-dose medicament delivery device |
| CN118924744A (zh) * | 2024-07-29 | 2024-11-12 | 复旦大学 | 小分子抑制剂ha15在抗乙型肝炎病毒中的应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5547594A (en) * | 1992-11-03 | 1994-05-24 | Secretech, Inc. | Microcrystalline cellulose as an immune adjuvant |
| US20030092145A1 (en) | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
| CN1193745C (zh) | 2001-02-27 | 2005-03-23 | 国家医药管理局上海医药工业研究院 | 一种鼻用鲑降钙素粉末吸入剂及制备方法 |
| CN1607941A (zh) | 2001-11-19 | 2005-04-20 | 贝克顿迪肯森公司 | 粒状药物组合物 |
| WO2003086443A1 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| EP1701738B1 (en) * | 2003-12-17 | 2015-03-11 | Wyeth LLC | Method for producing storage stable RSV compositions |
| US20060292173A1 (en) | 2004-12-13 | 2006-12-28 | Macadam Donald H | Multibacterial vaccines and uses thereof |
| PT1954308E (pt) | 2005-09-16 | 2011-11-03 | Merial Ltd | Estabilizadores para vacinas liofilizadas |
| BRPI0616879A2 (pt) | 2005-10-04 | 2011-07-05 | Alk Abello As | formulação de vacina sólida |
| EP1933867A1 (en) | 2005-10-04 | 2008-06-25 | Alk-Abello A/S | Solid vaccine formulation |
| AU2007215080A1 (en) | 2006-02-13 | 2007-08-23 | Fraunhofer Usa, Inc. | Influenza antigens, vaccine compositions, and related methods |
| EP2004226A1 (en) | 2006-03-24 | 2008-12-24 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Storage of influenza vaccines without refrigeration |
| ITMI20061117A1 (it) | 2006-06-09 | 2007-12-10 | Michele Bonanomi | Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi |
| US20080226729A1 (en) | 2006-09-08 | 2008-09-18 | Becton, Dickinson And Company | Stable powder formulations of alum-adsorbed vaccines |
| SG10202012986SA (en) * | 2006-09-29 | 2021-01-28 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
| CN101668544B (zh) * | 2006-12-26 | 2013-04-24 | 株式会社新日本科学 | 经鼻投用制剂 |
| CA2681567C (en) * | 2007-03-22 | 2016-07-19 | The Regents Of The University Of Colorado, A Body Corporate | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
| WO2009006299A2 (en) | 2007-06-29 | 2009-01-08 | Dr. Reddy's Laboratories Ltd. | Multi-particulate systems |
| ES2615390T3 (es) * | 2008-03-05 | 2017-06-06 | Sanofi Pasteur | Proceso para estabilizar una composición de vacuna que contiene adyuvante |
| CN101601860A (zh) * | 2008-06-13 | 2009-12-16 | 中国科学院过程工程研究所 | 疫苗 |
| MY172788A (en) | 2008-08-01 | 2019-12-12 | Gamma Vaccines Pty Ltd | Influenza vaccines |
| US9101539B2 (en) * | 2009-05-15 | 2015-08-11 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
| GB2472327B (en) * | 2009-07-31 | 2013-03-13 | Shin Nippon Biomedical Lab Ltd | Intranasal granisetron and nasal applicator |
| JP5491119B2 (ja) | 2009-10-02 | 2014-05-14 | 日東電工株式会社 | 薬物含有微粒子を含む医薬組成物およびその製造方法 |
| AU2012244074B2 (en) | 2010-04-15 | 2015-01-15 | Km Biologics Co., Ltd. | Methods and compositions for intranasal delivery |
| CN102933230B (zh) | 2010-04-15 | 2016-03-02 | 株式会社新日本科学 | 用于鼻内递送的方法和组合物 |
-
2011
- 2011-04-15 CN CN201180027287.1A patent/CN102933230B/zh active Active
- 2011-04-15 BR BR112012026116A patent/BR112012026116A2/pt not_active IP Right Cessation
- 2011-04-15 EP EP13189570.8A patent/EP2689785B1/en active Active
- 2011-04-15 KR KR1020197006392A patent/KR102136036B1/ko not_active Expired - Fee Related
- 2011-04-15 SG SG2012071841A patent/SG184304A1/en unknown
- 2011-04-15 CA CA2796593A patent/CA2796593C/en active Active
- 2011-04-15 ES ES13189570T patent/ES2874817T3/es active Active
- 2011-04-15 JP JP2012547369A patent/JP5771626B2/ja active Active
- 2011-04-15 CN CN2013100510480A patent/CN103126996A/zh active Pending
- 2011-04-15 KR KR1020127030060A patent/KR101960102B1/ko active Active
- 2011-04-15 US US13/640,623 patent/US9687536B2/en active Active
- 2011-04-15 CN CN201710415508.1A patent/CN107260689A/zh active Pending
- 2011-04-15 EP EP11768642.8A patent/EP2558120A4/en not_active Withdrawn
- 2011-04-15 WO PCT/JP2011/002225 patent/WO2011129120A1/en not_active Ceased
- 2011-04-15 RU RU2012144612/15A patent/RU2012144612A/ru not_active Application Discontinuation
- 2011-04-15 CA CA2993242A patent/CA2993242C/en active Active
- 2011-04-15 KR KR1020127025573A patent/KR20130083376A/ko not_active Ceased
-
2012
- 2012-10-12 CU CU2012000148A patent/CU20120148A7/es unknown
-
2013
- 2013-01-25 JP JP2013011673A patent/JP2013126989A/ja active Pending
- 2013-03-14 US US13/828,337 patent/US10463723B2/en active Active
-
2015
- 2015-09-24 JP JP2015186488A patent/JP2016006119A/ja active Pending
-
2017
- 2017-07-19 JP JP2017139598A patent/JP2017186377A/ja active Pending
-
2019
- 2019-03-05 JP JP2019039165A patent/JP6827488B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012144612A (ru) | Способ и композиции для интраназальной доставки | |
| JP2013126989A5 (https=) | ||
| Vassilieva et al. | Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature | |
| Quan et al. | Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization | |
| Quan et al. | Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles | |
| Patil et al. | Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine | |
| AU764368B2 (en) | Intranasal influenza virus vaccine | |
| Tonnis et al. | Devices and formulations for pulmonary vaccination | |
| JP6611720B2 (ja) | 熱安定性ワクチン製剤及びマイクロニードル | |
| US6793928B1 (en) | Vaccines with an LTB adjuvant | |
| CN1285753A (zh) | 透皮给药微粒疫苗组合物 | |
| Chen et al. | Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method | |
| JPWO2014103488A1 (ja) | 経鼻インフルエンザワクチン組成物 | |
| Tian et al. | Intradermal administration of influenza vaccine with trehalose and pullulan-based dissolving microneedle arrays | |
| Richert et al. | A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose | |
| Tomar et al. | Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge | |
| Zhou et al. | RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern | |
| Patil et al. | Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration | |
| Tomar et al. | Dry influenza vaccines: towards a stable, effective and convenient alternative to conventional parenteral influenza vaccination | |
| Liu et al. | Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing | |
| US9943592B2 (en) | Vaccine adjuvants from self-assembling peptides | |
| Sanders et al. | Single dose intranasal immunization with ISCOMATRIX™ vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract | |
| JP2020518646A (ja) | ワクチン組成物 | |
| Seid Jr et al. | Transcutaneous immunization with Intercell's vaccine delivery system | |
| JP2010501595A (ja) | 免疫応答を誘発または誘導する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160328 |